Methods: New Zealand White rabbits were anesthetized with ketamine and xylazine and instrumented for systemic blood pressure monitoring and spinal cord blood flow measurements using the microsphere method. After pretreatment with flunarizine or vehicle, ischemic spinal cord injury was created selectively in the caudal regions of the spinal cord by cross-clamping the abdominal aorta for a period of 25 minutes. Spinal cord blood flow was measured before, during, and 15 minutes after cross-clamp removal. Animals were allowed to recover and were graded neurologically at 18 and 24 hours after ischemia.
See Editorial Comment, page 1553 dative enzymes and, in specific nerve terminals, may stimulate the release of excitotoxic neurotransmitters.2 Both of these mechanisms could contribute to ongoing neuronal damage.' There is a significant accumulation of data concerning the effects of calcium antagonists in cerebral ischemia.3-9 Few studies have examined their use in spinal cord ischemia models.10"11 Most investigations have been aimed at examining the effect of calcium antagonists in spinal cord injury models with secondary ischemia.22 '15 A chemically distinct subgroup of calcium antagonist, the diphenylalkylamines, has been identified that is highly lipophilic and readily crosses the blood-brain barrier. Flunarizine (1-cinnamyl-4 [bis-(p-fluorophenyl)-methyl] piperazine hydrochloride) is representative of this subgroup and has a receptor-mediated effect on vascular smooth muscle as well as a direct effect on contractile proteins in smooth muscle tissue. 16 Flunarizine exhibits antivasospastic activity both in vitro and in vivo9'1718 and is a potent vasodilator with a predilection for cerebral vessels. '9 In a preliminary report flunarizine pretreatment improved neurological recovery after spinal cord ischemia in a rat model.10 The present study was undertaken to determine the effects of flunarizine on spinal cord blood flow (SCBF) and neurological recovery in a well-established model of spinal cord ischemia.
Materials and Methods Animal Preparation
Research was conducted in accordance with the Animal Welfare Act and the federal statutes and regulations relating to animals and experiments involving animals and adheres to the principles set forth in the Guide for the Care and Use of Laboratory Animals, National Institutes of Health Publication 85- 23, 1985 . Forty-two male New Zealand White rabbits (body weight, 2.5 to 3.5 kg) were anesthetized with an intramuscular injection of ketamine (50 mg/kg) and xylazine (8 mg/kg CO=cpm (S)-cpm (Syr)/R where S is standard, cpm is counts per minute, and Syr is syringe after injection. CO is expressed as milliliters per minute. Organ blood flow (BF) was then expressed in milliliters per minute per 100 g and determined as follows:
BF= Sample cpm/Sample Wt x 100/R Spillover among isotope detection windows was determined using microsphere isotope standards, and appropriate corrections were made in all tissue samples. When estimates of blood flow between paired organs differed by more than 20%, inadequate ventricular mixing was assumed and the animal was removed from the study.
Experimental Design
Four treatment groups and one control group provided the data for this study. Flunarizine was administered by intravenous slow bolus injection at 0.1, 0.3, 0.4, or 1.0 mg/kg. Aqueous vehicle was administered in a similar fashion.
Flunarizine was provided as a gift from A. Wauquier (Janssen Pharmaceutica, Beerse, Belgium). After baseline microsphere injection for blood flow determination, an intravenous bolus of flunarizine or vehicle was Results Flunarizine had marked effects on systemic arterial blood pressure (SABP) immediately after infusion. Results are depicted in Fig 2. The most profound and potentially clinically relevant levels of hypotension were associated with the 0.4-and 1.0-mg/kg doses. There was an associated reflex tachycardia, but no ectopy or arrhythmias were noted. The mean duration of the hypotensive event was 5 to 7 minutes after completion of the infusion, with a mean decline in SABP of 20 mm Hg. Spinal cord ischemia was not created until animals returned to baseline SABP. The possibility that a microsphere injection might exacerbate the hypotension precluded the measurement of SCBF and CO during the episode. Neither flunarizine infusion nor hypotension appeared to lower body temperature, which was a time-dependent, ambient temperature-dependent phenomenon. There was no association between transient hypotension and mortality.
Pretreatment CO was similar in all groups, with a mean of 540 mL-min' * 100 g-1, although there was great individual variation and a large SD of the mean.
Mean CO declined to 408 mL-min * 100 g`during the ischemic period but returned to at or near baseline by 15 minutes of reperfusion. Baseline SCBF to the cervical, thoracic, and lumbosacral segments, reported as mean-+-SD, were 63+13.6, 42.5+13.8, and 53.3+10.6 mL*min-1.100 g-1, respectively. Mean cerebral blood flow was 100±27 mL-min' * 100 g`1 and was not significantly influenced by flunarizine at any dose. The ischemic insult resulted in a significant drop in SCBF at all levels of the spinal cord, but most severe in the lumbosacral region. Cervical SCBF never declined below 25 mL * min . 100 g-', and flunarizine had no clear effect on ischemic or reperfusion blood flow. In the thoracic spinal cord, SCBF had a profile similar to that of lumbosacral flows with mean ischemic SCBF near 20 mL-min '. 100 g`1 in all but the 0.3-and 0.4-mg/kg treatment groups, in which mean SCBF was maintained above 25 mL. min . 100 g` (Fig 3) groups. Lumbosacral SCBF demonstrated the most profound decrements in ischemic flow, measuring 10, 13.5, 18, and 24 mL min' 100 g`1 in the 0.1-mg/kg, 1.0-mg/kg, vehicle, and 0.3-mg/kg treatment groups, respectively. The 0.4-mg/kg treatment group had a higher mean SCBF, but a large SEM precluded statistical significance. Reperfusion SCBF to the caudal regions of the spinal cord, unlike the thoracic regions, returned to baseline with only the 1.0-mg/kg treatment group demonstrating reperfusion hyperemia measuring 150% of baseline blood flow. When compared with vehicle, flunarizine failed to significantly alter or preserve ischemic or reperfusion SCBF at any of the doses used, despite a trend toward improvement in the 0.4-mg/kg treatment group (Fig 4) .
In our preliminary studies 88% of rabbits subjected to 25 However, it clearly prolonged the interval between drug administration and the production of ischemia. The effect of this short delay is unlikely to be significant, although we cannot say with certainty that there has been no pharmacologic selection either for or against the higher doses. The mechanism of this hypotension may be that flunarizine is exerting a direct effect on contractile smooth muscle in noncerebral resistance vessels in a time-and dose-dependent fashion. Flunarizine has been shown to increase both muscle and intestinal blood flow, which could lead to peripheral pooling of blood with resultant hypotension on that basis. However, this peripheral vascular effect has been seen with both higher and lower doses of flunarizine. 
